Why the world’s largest trio of vaccine makers failed on Covid-19
Despite their jab expertise, GlaxoSmithKline, Merck, and Sanofi were outdone by less recognisable names in the space
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 14 of 38
GlaxoSmithKline says FDA accepts new drug application for specialist anaemia treatment
Daprodustat has been developed for people also suffering from chronic kidney disease
GlaxoSmithKline boosts oncology product line as it swoops for US drug developer in US$1.9bn deal
Sierra Oncology's lead product has successfully navigated a phase III clinical trial
GlaxoSmithKline workers to vote on strike over 2.75% pay offer
Offers on the table amount to a pay cut in real terms, with the latest retail price inflation reaching 7.8% earlier this year
Hermes changes name to Evri, introduces employee pensions
In recent times, Aberdeen Standard Life transformed to Abrdn, Weight Watchers turned into Wellness and Wellbeing and Facebook changed its name to Meta.
GlaxoSmithKline devalued as it moves toward Haleon demerger - broker
Haleon demerger will refocus investors while positive data on RSV vaccine could accelerate closing of devaluation gap, says Berenberg
GlaxoSmithKline has European marketing application accepted for kidney disease drug
Company said marketing permission is biggest milestone for HIF-PHI daprodustat since Japanese approval
GlaxoSmithKline gets first Covid-19 vaccine approved
Canada has approved the jab, which was developed in collaboration with Medicago
GlaxoSmithKline and Sanofi plan to submit data from COVID-19 booster and Phase III trials for approval
Results from the Phase III trials were expected to be released last year
GlaxoSmithKline says demerger of consumer healthcare company Haleon on track for mid-2022
“Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders," GSK CEO Emma Walmsley
GlaxoSmithKline goes with Haleon as new name of its Consumer Healthcare division
On the plus side, the name does not have any seemingly raNdOm caPitAl letters in it
GlaxoSmithKline hits the pause button on RSV vaccination trial
Enrolment was halted on the advice of an independent data monitoring committee
GlaxoSmithKline investors would be glad of some positivity, but will they find it on Wednesday?
Glaxo, Barratt and Dunelm are among the notable names in the diary for Wednesday.
Archive
FTSE 100 closes higher with help from oil giants, banks and miners
The oil price is down but Shell and BP - the latter ahead of results - are on the rise
GlaxoSmithKline JV to receive US$1.25bn after HIV case settlement
It brings to an end a long-running legal wrangle with US giant Gilead Sciences
GlaxoSmithKline names Tony Wood chief scientific officer to succeed Hal Barron
Barron has been appointed as chief executive officer of the new US biotech company Altos Labs
GlaxoSmithKline shares rise after it rejects Unilever bid for its consumer healthcare division
GSK's board is under pressure from activist shareholders to sell the Consumer Healthcare business but it believes the £50bn Unilever bid undervalues the company.
Archive
FTSE 100 closes above 7,600 points on M&A boost
The Footsie has again risen above 7,600 but this time with a bit more authority
GlaxoSmithKline names ex-Tesco chief Sir Dave Lewis to chair consumer healthcare spin-off
The demerger of the consumer healthcare business will take place in mid-2022 and the new company will list on the London Stock Exchange
GlaxoSmithKline/Sanofi COVID-19 vaccine effective as booster shot, trial shows
"These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received"